[go: up one dir, main page]

UY32721A - Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados - Google Patents

Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados

Info

Publication number
UY32721A
UY32721A UY0001032721A UY32721A UY32721A UY 32721 A UY32721 A UY 32721A UY 0001032721 A UY0001032721 A UY 0001032721A UY 32721 A UY32721 A UY 32721A UY 32721 A UY32721 A UY 32721A
Authority
UY
Uruguay
Prior art keywords
hcv
viruses
pharmaceutical compositions
related methods
useful pharmaceutical
Prior art date
Application number
UY0001032721A
Other languages
English (en)
Inventor
William E Delaney
Mo Hongmei
Zhong Weidong
Original Assignee
Gilead Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Ltd filed Critical Gilead Sciences Ltd
Publication of UY32721A publication Critical patent/UY32721A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención está relacionada con combinaciones del Compuesto 1 y del Compuesto 2 que son útiles para tratar una infección causada por el virus de la hepatitis C.
UY0001032721A 2009-06-23 2010-06-18 Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados UY32721A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21964609P 2009-06-23 2009-06-23

Publications (1)

Publication Number Publication Date
UY32721A true UY32721A (es) 2011-01-31

Family

ID=42536374

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032721A UY32721A (es) 2009-06-23 2010-06-18 Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados

Country Status (5)

Country Link
US (1) US20100324059A1 (es)
AR (1) AR077138A1 (es)
TW (1) TW201113279A (es)
UY (1) UY32721A (es)
WO (1) WO2010151487A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505897A (ja) * 2008-10-15 2012-03-08 インターミューン・インコーポレーテッド 治療用抗ウイルス性ペプチド
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
RU2012117395A (ru) * 2009-09-28 2013-11-10 Ф.Хоффманн-Ля Рош Лтд Новые макроциклические ингибиторы репликации вируса гепатита с
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
WO2012009394A2 (en) * 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication
PH12014500832A1 (en) 2011-10-21 2022-12-02 Abbvie Inc Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP5677646B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド Ｈｃｖの治療に使用するためのｄａａの（例えばａｂｔ−０７２もしくはａｂｔ−３３３との）併用治療
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20070015553A1 (en) 2005-07-12 2007-01-18 Microsoft Corporation Compact and durable clamshell smartphone
TWI399377B (zh) * 2006-07-07 2013-06-21 Gilead Sciences Inc 類鐸受體７之調節劑
AU2007269614B2 (en) 2006-07-07 2011-09-08 Gilead Sciences, Inc. Novel pyridazine compound and use thereof
CN101784548B (zh) * 2007-06-29 2013-07-17 吉里德科学公司 嘌呤衍生物及其作为toll样受体7的调节剂的用途

Also Published As

Publication number Publication date
WO2010151487A1 (en) 2010-12-29
US20100324059A1 (en) 2010-12-23
AR077138A1 (es) 2011-08-03
TW201113279A (en) 2011-04-16

Similar Documents

Publication Publication Date Title
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
MX344092B (es) Compuestos antivirales.
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
MX346264B (es) Compuestos antivirales.
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
EA201390190A1 (ru) Ингибиторы вируса гепатита с
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
CO6440581A2 (es) Inhibidores del virus de la hepatitis c
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA201270622A1 (ru) Ингибиторы вируса гепатита с
ECSP14013315A (es) Inhibidores de aplicación viral
EA201391152A1 (ru) Ингибиторы вируса гепатита с
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
UY32457A (es) Vacuna del virus del dengue inactivado
UY34066A (es) Inhibidores del virus de la hepatitis c
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
CL2016000300A1 (es) Métodos terapéuticos
CO6290645A2 (es) Compuesto para el tratamiento de la hepatitis c
AR057641A1 (es) Compuestos 5- nitro - nucleosidos para tratar infecciones virales
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190219